Literature DB >> 21654638

MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma.

Kentaro Kojima1, Akemi Takata, Charles Vadnais, Motoyuki Otsuka, Takeshi Yoshikawa, Masao Akanuma, Yuji Kondo, Young Jun Kang, Takahiro Kishikawa, Naoya Kato, Zhifang Xie, Weiping J Zhang, Haruhiko Yoshida, Masao Omata, Alain Nepveu, Kazuhiko Koike.   

Abstract

α-fetoprotein (AFP) is not only a widely used biomarker in hepatocellular carcinoma (HCC) surveillance, but is also clinically recognized as linked with aggressive tumour behaviour. Here we show that deregulation of microRNA122, a liver-specific microRNA, is a cause of both AFP elevation and a more biologically aggressive phenotype in HCC. We identify CUX1, a direct target of microRNA122, as a common central mediator of these two effects. Using liver tissues from transgenic mice in which microRNA122 is functionally silenced, an orthotopic xenograft tumour model, and human clinical samples, we further demonstrate that a microRNA122/CUX1/microRNA214/ZBTB20 pathway regulates AFP expression. We also show that the microRNA122/CUX1/RhoA pathway regulates the aggressive characteristics of tumours. We conclude that microRNA122 and associated signalling proteins may represent viable therapeutic targets, and that serum AFP levels in HCC patients may be a surrogate marker for deregulated intracellular microRNA122 signalling pathways in HCC tissues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21654638     DOI: 10.1038/ncomms1345

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  58 in total

Review 1.  Role of microRNAs in plant and animal development.

Authors:  James C Carrington; Victor Ambros
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

2.  CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness.

Authors:  Patrick Michl; Antoine R Ramjaun; Olivier E Pardo; Patricia H Warne; Martin Wagner; Richard Poulsom; Corrado D'Arrigo; Kenneth Ryder; Andre Menke; Thomas Gress; Julian Downward
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

3.  Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.

Authors:  Yinghui Zhou; William M Rideout; Tong Zi; Angela Bressel; Shailaja Reddypalli; Rebecca Rancourt; Jin-Kyeung Woo; James W Horner; Lynda Chin; M Isabel Chiu; Marcus Bosenberg; Tyler Jacks; Steven C Clark; Ronald A Depinho; Murray O Robinson; Joerg Heyer
Journal:  Nat Biotechnol       Date:  2009-12-20       Impact factor: 54.908

4.  p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression.

Authors:  S K Ogden; K C Lee; K Wernke-Dollries; S A Stratton; B Aronow; M C Barton
Journal:  J Biol Chem       Date:  2001-09-25       Impact factor: 5.157

5.  Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure.

Authors:  Laurent Sansregret; Charles Vadnais; Julie Livingstone; Nicholas Kwiatkowski; Arif Awan; Chantal Cadieux; Lam Leduy; Michael T Hallett; Alain Nepveu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

6.  The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Authors:  Riccardo Taulli; Francesca Bersani; Valentina Foglizzo; Alessandra Linari; Elisa Vigna; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

7.  Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.

Authors:  Chantal Cadieux; Valérie Kedinger; Lu Yao; Charles Vadnais; Maria Drossos; Marilène Paquet; Alain Nepveu
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

8.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

9.  Cux-1 transgenic mice develop glomerulosclerosis and interstitial fibrosis.

Authors:  Jennifer G Brantley; Madhulika Sharma; Neal I Alcalay; Gregory B Vanden Heuvel
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

10.  A mammalian microRNA expression atlas based on small RNA library sequencing.

Authors:  Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

View more
  54 in total

Review 1.  The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC).

Authors:  Lifeng Wang; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2011-10-10       Impact factor: 11.530

Review 2.  The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-11-21       Impact factor: 7.527

3.  Novel insights into the molecular mechanisms of α-fetoprotein expression and malignant phenotypes of hepatocellular carcinoma.

Authors:  Zhiqing Hu; Weihua Zhao
Journal:  Cell Mol Immunol       Date:  2011-08-22       Impact factor: 11.530

Review 4.  Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma.

Authors:  Chikako Shibata; Motoyuki Otsuka; Takahiro Kishikawa; Motoko Ohno; Takeshi Yoshikawa; Akemi Takata; Kazuhiko Koike
Journal:  World J Hepatol       Date:  2015-01-27

5.  Impact of CUX2 on the female mouse liver transcriptome: activation of female-biased genes and repression of male-biased genes.

Authors:  Tara L Conforto; Yijing Zhang; Jennifer Sherman; David J Waxman
Journal:  Mol Cell Biol       Date:  2012-09-10       Impact factor: 4.272

Review 6.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 7.  MicroRNAs and liver disease.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Mari Yamagami; Motoko Ohno; Akemi Takata; Chikako Shibata; Rei Ishibashi; Kazuhiko Koike
Journal:  J Hum Genet       Date:  2016-05-26       Impact factor: 3.172

Review 8.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

Review 9.  Stem cells in liver diseases and cancer: recent advances on the path to new therapies.

Authors:  C Bart Rountree; Lopa Mishra; Holger Willenbring
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

10.  Upregulated Expression of CUX1 Correlates with Poor Prognosis in Glioma Patients: a Bioinformatic Analysis.

Authors:  Xiujie Wu; Fan Feng; Chuanchao Yang; Moxuan Zhang; Yanhao Cheng; Yayun Zhao; Yayu Wang; Fengyuan Che; Jian Zhang; Xueyuan Heng
Journal:  J Mol Neurosci       Date:  2019-08-03       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.